1.63

0.62% 0.010

After Hours: 1.62 -0.010 -0.61%

Medicinova Inc (MNOV)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Medicinova Inc stock is traded at $1.63, with a volume of 96,718. It is up +0.62% in the last 24 hours and up +25.38% over the past month. MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Previous Close:

$1.62

Open:

$1.62

24h Volume:

96,718

Relative Volume:

1.96

Market Cap:

$80.23M

Revenue:

$596.60K

Net Income/Loss:

$-11.72M

P/E Ratio:

-6.8315

EPS:

-0.2386

Net Cash Flow:

$-9.51M

1W Performance:

+13.59%

1M Performance:

+25.38%

6M Performance:

+13.19%

1Y Performance:

+21.26%

1-Day Range:

$1.55

$1.63

1-Week Range:

$1.42

$1.63

52-Week Range:

$1.168

$1.96

Medicinova Inc Stock (MNOV) Company Profile

Name

Medicinova Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

858-373-1500

Address

4275 EXECUTIVE SQUARE, LA JOLLA, CA

Employee

Twitter

@MedicinovaJapan

Next Earnings Date

2026-08-13

Latest SEC Filings

MNOV's Discussions on Twitter

Compare MNOV vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNOV Medicinova Inc	1.63	67.43M	596.60K	-11.72M	-9.51M	-0.2386
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Medicinova Inc Stock (MNOV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	H.C. Wainwright	Buy
Mar-10-21	Initiated	Maxim Group	Buy
Mar-25-19	Resumed	B. Riley FBR	Buy
Mar-28-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-18-17	Initiated	Credit Suisse	Outperform
Jan-04-13	Reiterated	Ladenburg Thalmann	Buy
May-24-12	Downgrade	MLV & Co	Buy → Hold
Oct-18-11	Reiterated	MLV Capital	Buy
Jun-22-11	Initiated	Global Hunter Securities	Buy
May-12-10	Initiated	Wedbush	Outperform
Nov-12-08	Reiterated	Ladenburg Thalmann	Buy
May-15-08	Initiated	Rodman & Renshaw	Mkt Outperform
Jul-09-07	Initiated	Punk, Ziegel & Co	Buy

View All

Medicinova Inc Stock (MNOV) Latest News

Sep 05, 2026

MediciNova stock gains as price moves above 200-day line - AD HOC NEWS

Sep 05, 2026

Sep 04, 2026

MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates - Kalkine

Sep 04, 2026

Sep 02, 2026

MediciNova Ends Standby Equity Financing Agreement - TipRanks

Sep 02, 2026

MediciNova (MNOV) ends $30M stock-sale deal after tapping only a fraction of it - Stock Titan

Sep 02, 2026

Aug 27, 2026

MediciNova Updates Executive Contracts, Enhancing Change-in-Control Protection - TipRanks

Aug 27, 2026

Aug 24, 2026

Medicinova (MNOV) Outlook: Closes 8.57% Higher at $1.52 in the Latest Reading; Market Levels: $1.44 and $1.60 Define the Nearby Reference Levels in Latest TradingVolatility Smile - vinanet.vn

Aug 24, 2026

Aug 20, 2026

Medicinova (MNOV) Financial Update: Profit Per Share Surpasses Its Benchmark in the Current Update; After Results: The Market Price Declines 2.90% at the CloseEPS Growth Rate - vinanet.vn

Aug 20, 2026

MediciNova, Inc. (NASDAQ:MNOV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 20, 2026

Aug 19, 2026

Form 8K MediciNova Inc For: 19 August By Investing.com - Investing.com Nigeria

Aug 19, 2026

MediciNova updates executive employment agreements for CEO and CMO By Investing.com - Investing.com South Africa

Aug 19, 2026

MediciNova updates executive employment agreements for CEO and CMO - Investing.com

Aug 19, 2026

Aug 18, 2026

FY2026 EPS Estimates for MediciNova Lowered by HC Wainwright - MarketBeat

Aug 18, 2026

Aug 17, 2026

FY2028 EPS Estimates for MediciNova Lowered by HC Wainwright - MarketBeat

Aug 17, 2026

Aug 14, 2026

Medicinova (MNOV) Holds Steady at $1.31 as Clinical-Stage Biotech Trades Within RangeWave Alternation - Vinanet

Aug 14, 2026

Aug 13, 2026

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts

Aug 13, 2026

MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results - MarketBeat

Aug 13, 2026

MediciNova Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

MediciNova: Q2 Earnings Snapshot - AOL.com

Aug 13, 2026

MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027 - TradingView

Aug 13, 2026

MNOV Q2'26 Earnings: EPS estimate is (0.06) USD - TradingView

Aug 13, 2026

Aug 10, 2026

MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss, But Stock Slips 1.49%High Estimate Range - vinanet.vn

Aug 10, 2026

Aug 07, 2026

MediciNova Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

Aug 07, 2026

MNOV Q2'26 Earnings: revenue estimate is 75.00K USD - TradingView

Aug 07, 2026